Dupuytren disease is a fibroproliferative disease of the palmar fascia of the hand. Its prevalence has been the subject of several reviews; however an accurate description of the prevalence range in the general population -and of the relation between age and Dupuytren disease -is lacking.
INTRODUCTION
Dupuytren disease is a fibroproliferative disease that affects the palmar fascia of the hand. This results in the development of nodules and cords, which eventually may contract and give rise to flexion contractures of the affected fingers.
The origin of Dupuytren disease has been attributed to both genetic and environmental factors. The results of several family studies -and, more specific, twin studies -suggested that Dupuytren disease has a strong genetic component. [1] [2] [3] In 2011, Dolmans et al. 4 performed a genome-wide association study in which 9 genes that are associated with Dupuytren disease were identified. Some environmental risk factors include excessive alcohol consumption, smoking, manual work and hand trauma. 5, 6 In addition, several diseases, such as diabetes mellitus and epilepsy, are thought to play a role in the etiology of Dupuytren disease. [7] [8] [9] However, the role of these risk factors and diseases is not fully elucidated, and the results of different studies are occasionally conflicting.
Many articles about the prevalence of Dupuytren disease have been published. [10] [11] [12] [13] [14] [15] In these articles there is a wide range of prevalence rates, varying from 0.2% to 56%, 16, 17 as reported in a previous literature review. 18 This wide range, in our opinion, may at least partly be caused by the great heterogeneity between study populations, such as healthy populations, participants with certain risk factors as well as patients with specific diseases. Suboptimal design of the included studies may also be a reason for the wide range.
Until now, no systematic review was conducted to scrutinize the prevalence rates specifically in the general population, i.e. a healthy non-hospital population. It is assumed that life expectancy will increase considerably in the coming decades, 19 and from our clinical experience we know that Dupuytren disease is a chronic disease of the elderly. Therefore, it will be important to enhance our knowledge about prevalence rates in the general population, and to be aware of changes in the prevalence across age. Furthermore, new treatment options have emerged, such as radiotherapy, percutaneous needle fasciotomy, and collagenase injection, and prevalence rates may be used to evaluate their cost effectiveness.
The aim of this study was to specify the prevalence range of Dupuytren disease in the general population, i.e. a healthy nonhospital population. This was done by reviewing the literature on prevalence of Dupuytren disease systematically, 2 combined with a quality assessment of the included studies. A secondary goal was to perform a meta-analysis on the relation between age and prevalence of Dupuytren disease.
METHODS

Literature search
Our final literature search was performed on May 9, 2012, 
Assessment of relevant studies
Two authors independently assessed the studies in three rounds, based on predefined criteria (Table 1) , and Cohen's kappa was calculated for each round. If in the first round the inclusion or exclusion criteria could not be assessed from the title and abstract, a full-text analysis was performed. After each round, discrepancies were discussed to reach consensus. The third author was consulted if no consensus could be reached.
Quality assessment of included studies
We used the scoring instrument of Cho and Bero 20 to assess the quality of the studies, based on a review article on quality assessment tools for epidemiologic studies. 21 The instrument consists of 24 questions about study design, participants, methods to control bias, statistical analyses, reporting of results, and the conclusions drawn from the results.
For each question respectively 2, 1, 0, and 0 points were awarded to the answers "Yes", "Partial", "No", and "Not applicable", in order to obtain an overall quality score for each article. This was done for each question except for the question on study design; in that case 1 to 5 points were given (1 for case reports, 2 for time series or uncontrolled experiments, 3 for cohort or case-control studies, 4 for nonrandomized controlled trials, and 5 for randomized controlled trials). 20 Total points awarded for the 24 questions were divided by the total possible points (the sum of the maximum points for each item, excluding "Not applicable" items) to generate a fraction between 0 and 1. A score of 1 represents the highest quality. 20 
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All papers that were included after the second full text round were scored with this instrument by the two authors independently. The article by Lanting et al. 22 was evaluated by DCB and an independent clinical epidemiologist to avoid a conflict of interest.
Data extraction and statistical analysis
In a statistical analysis, we combined studies that provided information on prevalence and sample sizes for different age categories in a total population, or in men and women separately. The aim of this meta-analysis was to determine a population-averaged relationship between age and Dupuytren disease, and to study possible heterogeneity in this relationship between studies. The midpoints of the age categories were used in a generalized linear mixed model. The form of the ageprevalence relationship was selected equal to an asymmetric logistic function with a random intercept for study to address possible heterogeneity. This model was applied to the data of men and women simultaneously with a random intercept for men and women that was correlated. A simpler model with only one random intercept was applied to the totals of men and women, since some studies did not provide data separately by sex. From the estimated models and the random effects, a range of age based predicted prevalences were estimated (i.e. 95% prediction intervals).
Additionally, in case heterogeneity was present, it was investigated whether the overall quality score, the quality of study design or geographical location affects the heterogeneity.
In some of the studies, the prevalence was determined in patients with a specific disease, and in a control group. If that was the case, only the data from the control group were used. The calculation of the exact 95% confidence intervals for the overall proportion of Dupuytren disease was calculated using the F-distribution. 23 
RESULTS
Results of literature search and assessment of relevant studies
The search resulted in 212 papers. After excluding duplicates and critical appraisal of the studies by predefined criteria (Table 1) , 23 studies were included ( Figure 1 ).
Two main reasons led to exclusion: first, the prevalence of Dupuytren disease was not determined, and second, the study population was not a general population.
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As a consequence also all non-English papers were excluded. To quantify the decisions in the selection process, we calculated a Cohen's kappa for each round of assessment; title and abstract (κ = 0.623, p < 0.001); full text round 1 (κ = 0.449, p = 0.001); and full text round 2 (κ = 0.528, p = 0.001). As shown in Table 2 , papers were published between 1972 and 2013. In some studies, only data from the control group were used (noted as CG in Table 2 ). 13, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Several times, these control groups were chosen from a population that sustained hand pathology. 25, 29, 30 In two studies, it was explicitly noted that the control group did not suffer from hand pathology. 31, 34 The total number of participants in the included studies ranged from 37 to 97,537, and in seven of these studies only men participated. 28, 33, [35] [36] [37] [38] [39] Age ranged from 18 to 100 years, with an average above 50 years in 12 studies. In six studies age was only reported in categories, without absolute number of participants in each category, so it was not possible to calculate a mean age (CAT in Table 2 ). 24, 29, 34, [39] [40] [41] The lowest prevalence found was 0.6% compared with 31.6% as highest prevalence over all age groups. 12, 32 In two studies, Dupuytren disease was diagnosed in a different fashion compared with the other studies. Descatha et al. did not include palmar thickening as sign of Dupuytren disease, and Lucas et al. excluded the thumb from examination. 37, 38 The quality score is depicted in the last column of Table 2 , this score ranged from 0.23 to 0.80. Table 3 shows in detail the results of the quality assessment per question, and Table 4 shows the score on the different questions per study. Question 2 is an open question which does not contribute to the final score.
Results of quality assessment
The majority of studies reported the study question only partially. In 13% of the papers, the inclusion and exclusion criteria were completely explained, while in 61% these criteria were not depicted at all. In almost 80% of the studies, the subjects were not randomly selected from the target population, or this was not reported. Only one of the 23 studies reported a sample size justification. 22 Regarding the statistical analyses, almost a quarter of the papers did not report which analyses were performed, and in only 52%, the performed analyses were fully appropriate to answer the research question. The effect of confounders was most frequently corrected in the statistical analyses, and not beforehand in the study design. In 70%, the conclusion of the study was fully supported by the findings. However, in one study the results point to a contrary conclusion than that reported. 29
Explorative analysis
The generalized linear mixed model indicated substantial heterogeneity between studies, meaning that prevalence varies between studies. It was explored whether the overall quality score and the subscore on methodology (questions 1, 4, 7-9, Was the study question sufficiently described?
Was the study design appropriate to answer the study question?
Were both inclusion and exclusion criteria specified?
For case studies only: Were patient characteristics adequately reported?* 0 (0%) 0 (0%) 0 (0%) 23 (100%) 7
Were subjects appropriate to the study question?
Were control subjects appropriate? 12 (52%) 6 (26%) 5 (22%) 0 (0%) 9
Were subjects randomly selected from the target population?
10 If subjects were randomly selected, was the method of random selection sufficiently well described?
11 If subjects were randomly allocated to treatment groups, was method of random allocation sufficiently described?** 0 (0%) 0 (0%) 0 (0%) 23 (100%)
12 If blinding of investigators was possible, was it reported?** 0 (0%) 0 (0%) 0 (0%) 23 (100%) 13 If blinding of subjects to intervention was possible, was it reported?** (0%) 0 (0%) 0 (0%) 23 Table 4 , ‡ Open question which does not contribute to final score, * Case studies were not included, so question 6 was not applicable for each of the included articles, ** Questions were not applicable, because this concerns intervention studies. Table 4 ) were related to the heterogeneity. The goal of this analysis was to check whether selecting studies on quality would narrow the prevalence range substantially. The distance of each study to the median profile in Figure 2 was plotted against the variables of interest. No clear pattern was observed for the quality scores or the subscores; both low-and high-quality studies appear on both sides of the median prevalence for all levels. This indicates that the quality of a study did not explain the variation in prevalence, so no studies were excluded for further analyses based on quality score. Furthermore, we investigated whether the heterogeneity was explained by the geographical location (i.e. whether the relative difference of a study to the median age-related prevalence fits with an order in geographical location), but no clear trend was visible. For example, the prevalence found by both Bennett 28 and Burke et al. 35 was below the median age-related prevalence curve and the prevalence found by Arafa et al. 24 was above this median, whereas they all came from the same geographical location: England. On the other hand, prevalences in the Nordic countries all seem to be below the median curve. Instead of trying to understand the influence of geographic location, we calculated, based on our 
14-17, 19 in
24:
Findings support the conclusion. Question 1 was scored 3 (cohort design) or 2 (cross-sectional design), other questions were scored 2 (yes), 1 (partial), 0 (no), NA (not applicable).
The score was calculated by dividing the total points by the maximum possible points. A higher score represents a higher quality. 36 model, 95% prediction limits (the outer limits in Figure 2 ). These limits indicate the range of expected true age-related prevalence of Dupuytren disease in observed and unobserved geographical locations in Western countries.
Relation between age and prevalence of Dupuytren disease
A combined analysis of 10 studies 12, 15, 22, 24, 29, 30, 34, [40] [41] [42] representing information on prevalences in different age groups showed an overall relationship that is visualized in the upper graph of Figure 2 . In the center and lower graphs of Figure 2 , this relationship is shown respectively for women (8 studies 12, 15, 22, 24, 34, [40] [41] [42] ) and men (11 studies. 12, 15, 22, 24, 28, 34, 35, 37, [40] [41] [42] The prevalence is shown, as well as the 95% confidence intervals (inner dotted lines), taking into account the heterogeneity between studies.
Furthermore, a 95% prediction interval is presented (outer dashed lines), which makes it possible to predict the prevalence at a certain age in a healthy nonhospital population. For instance, the overall prevalence of Dupuytren disease is estimated 12% at 55 years, and 29% at an age of 75 years. The prediction band can be used to estimate the a priori prevalence in a random sample at different ages and geographical locations. Clearly, the prevalence increases with rising age. Furthermore, the graphs show that the prevalence of Dupuytren disease is higher in men than in women.
In addition, the age of onset is lower in men compared with the age of onset in women.
Investigating the goodness of fit of the estimated models, the R 2 was calculated between the observed numbers of Dupuytren disease, and the predicted numbers of Dupuytren disease from the model. For men, the R 2 was estimated at 99.5%, for women the R 2 was equal to 93.0% and for men and women together the R 2 was 97.5%, which demonstrates a good fit of the generalized linear mixed model. This indicates that the models in Figure 2 are able to predict new observations with high certainty. The high goodness of fit may not seem in line with the observed outliers outside the prediction limits in Figure 2 . However, several of these outliers were based on small number of subjects (Table 5 ). For instance, when only one subject is observed in an age category, the prevalence can only be estimated at either 100% or 0% depending on the outcome of Dupuytren disease. The prediction intervals hold true for relative large sample sizes.
2 Figure 2 . Relationship between age and Dupuytren prevalence, presented for totals, and men and women separately. Dotted lines: 95% confidence interval. Dashed lines: 95% prediction interval.
Dots: individual prevalence estimates used in the analysis.
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DISCUSSION
Dupuytren disease is a hand disorder that is often progressive and eventually can cause contractures of the affected fingers. The reported prevalence rates of Dupuytren disease vary widely in the literature. Therefore, the primary goal of this systematic review was to come to a more accurate distribution of the prevalence of Dupuytren disease in the general population. A secondary goal was to perform a meta-analysis on the relation between prevalence of Dupuytren disease and age.
To our knowledge, this systematic review is the first of its kind. First, it focuses on prevalence rates specifically in the general population of Western countries (i.e. a healthy nonhospital population), excluding specific patient groups. Second, the quality of the studies was critically assessed. Previous reviews about prevalence of Dupuytren disease concern different kinds of populations, such as manual workers, 43 rock climbers, 44, 45 and a mixture of healthy participants and patients with a specific disease. 18 Furthermore, geographical location was studied and we performed a thorough meta-analysis on the relationship between age and Dupuytren disease.
Our English search strategy was performed in English databases, so we might have missed relevant papers in foreign languages. However, despite this limitation, several papers in foreign languages, such as German, French and Italian, entered the full text analysis. The Cohen's kappa for each round of assessment was moderate, emphasizing the necessity of discussing the assessment with multiple authors.
After the full text analysis, 23 studies were included, with the number of participants ranging from 37 to 97,537 in the age of 18 to 100 years. Prevalence in these studies varied from 0.6% to 31.6%, which is a smaller range than previously published. 18 During the quality assessment we came across a number of noteworthy points. First, only few studies reported that they applied sampling to select their participants. 15, 22, 24, 25, 37 However, three of these studies did not describe the method of sampling. 24, 25, 37 If participants are not randomly selected the risk of selection bias increases, which makes it difficult to extrapolate data from these studies.
Second, only one study reported a sample size justification. 22 In an observational study, the accuracy of the estimates (i.e. the prevalence) depends on sample size. 46 If a sample size is not calculated beforehand, the results of the study might be less precise than intended. Finally, in only a quarter of the studies the statistical tests were fully stated, and in 52% the analyses were completely appropriate. To enlarge 2 Figure 2 (Y-axis ranges from 0 -80%).
the reproducibility of the results, it is essential that such information is properly documented. More importantly, to ensure that correct conclusions will be drawn, it is crucial that appropriate analyses are performed.
To narrow the prevalence range, we intended to select studies for further analysis,
based on their quality. The final overall quality score differed from 0.23 to 0.80.
However, in the explorative analysis, no relation was found between this quality score and the reported prevalence. This is in accordance with the findings in a metaanalysis in which the meta-odds ratio for manual work and vibration exposure of all 40 studies was similar to the meta-odds ratio of only high quality studies. 43 Several papers have been published about the difficulties using an overall score to assess the quality of a study. [47] [48] [49] With an overall quality score it is hard to discriminate between poor reporting and poor methodology of the study. Thus, it is advised to evaluate papers based on key components rather than an overall score. 21, 48, 50 Therefore, we analyzed the relation between a high score on methodology and the prevalence of Dupuytren disease. Still, no link was found, so we assumed that the current spread in prevalence was not based on a difference in quality of the studies, but on heterogeneity of the study populations.
We aimed to include studies with participants from a general population.
However, we ended with studies that did not provide information about race and that originated mainly from Europe. Nonetheless, the biogeographic regions in Europe differ from Arctic to Mediterranean. Based on our model, we suppose that the prevalence in different geographical locations lies within the prediction interval of Figure 2 , but more thorough analyses with additional variables are necessary to clarify and understand the geographic influence on the prevalence of Dupuytren disease.
As mentioned in the results, two studies diagnosed Dupuytren disease differently than other studies. 37, 38 Although this did not change our prevalence range substantially, differences in diagnosing Dupuytren disease complicate the comparison of results.
Preferably, all stages of Dupuytren disease in all rays are taken into account, for example by using the classification of Iselin 51 or Tubiana. 52 Furthermore, there were differences in reporting age; 6 studies reported age in categories, without giving the actual range. 24, 29, 34, [39] [40] [41] The discrepancies in reporting age also impede comparison of prevalence rates of different studies. Fortunately, we have been able to use data of different age categories in our meta-analysis.
It is well recognized that prevalence of Dupuytren disease increases with rising age. However, until now, a thorough analysis on this relationship was lacking. In our meta-analysis, we investigated this relationship by using all studies that provided information on prevalence in different age categories. We presented the relationship between age and Dupuytren disease, including 95% confidence intervals and 95% prediction intervals. The graphs can be used to determine a common estimate for the prevalence of Dupuytren disease at different ages, both for the total population 2 as well as for men and women separately. Nowadays, still little is known about the prevalence of Dupuytren disease in younger people, since in most studies an age over 50 years was one of the inclusion criteria. However, the relationship between age and prevalence presented in this paper already provides a first indication for prevalence at younger age.
CONCLUSION
The prevalence of Dupuytren disease in the general population of Western countries ranges from 0.6 to 31.6%. With the results of our meta-analysis, we have been able to present the relationship between prevalence of Dupuytren disease and age, including confidence intervals and prediction intervals. With the presented graphs it is possible to determine the prevalence at a certain age for the total general population of western countries, and for men and women separately.
ACKNOWLEDGEMENT
The authors would like to thank Professor P.U. Dijkstra, PhD for performing the quality assessment of the study in which some of the authors participated.
